Tasisulam 200 mg | 99.97%
TargetMol
Tasisulam is an apoptosis inducer and an antitumor agent via the intrinsic pathway.
More Information Supplier PageTasisulam
Search Results
Tasisulam 100 mg | 99.97%
TargetMol
Tasisulam is an apoptosis inducer and an antitumor agent via the intrinsic pathway.
More Information Supplier PageTasisulam
Mirdametinib 200 mg | 99.91%
TargetMol
PD0325901 is a specific and non-ATP-competitive MEK inhibitor (IC50: 0.33 nM).
More Information Supplier PageMirdametinib
GNE-617 10 mg | 99.86%
TargetMol
GNE-617, a specific NAMPT inhibitor(IC50=5 nM), shows potency in xenograft models of cancer.
More Information Supplier PageGNE-617
GNE-617 5 mg | 99.86%
TargetMol
GNE-617, a specific NAMPT inhibitor(IC50=5 nM), shows potency in xenograft models of cancer.
More Information Supplier PageGNE-617
GNE-617 2 mg | 99.86%
TargetMol
GNE-617, a specific NAMPT inhibitor(IC50=5 nM), shows potency in xenograft models of cancer.
More Information Supplier PageGNE-617
GNE-617 1 mg | 99.86%
TargetMol
GNE-617, a specific NAMPT inhibitor(IC50=5 nM), shows potency in xenograft models of cancer.
More Information Supplier PageGNE-617
Flumatinib 200 mg | Purity Not Available
TargetMol
Flumatinib is an orally bioavailable tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity.
More Information Supplier PageFlumatinib
Flumatinib 100 mg | Purity Not Available
TargetMol
Flumatinib is an orally bioavailable tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity.
More Information Supplier PageFlumatinib
Flumatinib 50 mg | Purity Not Available
TargetMol
Flumatinib is an orally bioavailable tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity.
More Information Supplier PageFlumatinib